An extensive analysis of national healthcare data has illuminated a persistent challenge within geriatric care: millions of older adults diagnosed with dementia continue to be prescribed medications known to heighten the risks of falls, cognitive deterioration, and subsequent hospitalization, despite years of established medical guidance advocating for extreme caution. This concerning trend was brought to light by new research, published on January 12 in the esteemed peer-reviewed journal JAMA, which revealed that approximately one in every four Medicare beneficiaries living with dementia received such medications during the study period.
While the overall prescription rates for these specific types of drugs have seen a gradual decrease across the entire Medicare population over the nine years examined, falling from 20% to 16%, individuals grappling with cognitive impairment remain disproportionately affected. This is particularly troubling as this demographic is inherently more susceptible to the adverse consequences associated with these medications, including increased frailty, disorientation, and a greater likelihood of experiencing falls that can lead to severe injuries and prolonged hospital stays.
The study’s senior author, Dr. John N. Mafi, an associate professor-in-residence of medicine at UCLA’s David Geffen School of Medicine, expressed his concerns, stating that while the general downward trend in prescriptions was a positive indicator, the persistence of high prescribing rates among vulnerable populations is deeply troubling. He further highlighted that in the final year of the study, over two-thirds of patients receiving these prescriptions lacked a clearly documented clinical justification, suggesting a significant prevalence of potentially inappropriate and harmful prescribing practices. Dr. Mafi elaborated on the disparity, noting that older adults with cognitive impairment were more likely to receive these medications compared to those with normal cognitive function, thereby exposing them to a heightened risk of severe adverse reactions. These findings, he concluded, underscore a substantial need for improvements in the quality and safety of care delivered to millions of elderly Americans.
To thoroughly investigate the nuances of medication prescribing patterns, the research team employed a rigorous methodology. They meticulously analyzed survey data meticulously collected through the Health and Retirement Study, a longitudinal survey of American households that tracks the health, retirement, and family economic circumstances of people over age 50. This survey data was then systematically linked with Medicare fee-for-service claims, providing a comprehensive picture of healthcare utilization and prescription patterns. The study’s temporal scope spanned from January 1, 2013, through December 31, 2021, allowing for an examination of trends over a substantial nine-year period. The older adult participants were strategically categorized into three distinct groups based on their cognitive status: individuals exhibiting normal cognitive function, those identified with cognitive impairment but without a formal dementia diagnosis, and finally, individuals with a confirmed diagnosis of dementia. This stratification was crucial for understanding how prescribing practices differed across varying levels of cognitive health.
The analytical focus of this comprehensive investigation centered on five specific categories of central nervous system (CNS)-active medications that have been associated with a higher risk profile in older adults. These included antidepressants exhibiting strong anticholinergic properties, which can impair cognitive function and contribute to dry mouth, blurred vision, and constipation; antipsychotic medications, often used to manage behavioral symptoms associated with dementia but carrying risks of movement disorders and sedation; barbiturates, a class of sedatives that can lead to respiratory depression and cognitive impairment; benzodiazepines, commonly prescribed for anxiety and insomnia, which can cause drowsiness, confusion, and an increased risk of falls; and non-benzodiazepine hypnotics, also used for sleep disturbances, which can similarly lead to next-day drowsiness and impaired coordination. The inclusion of these specific drug classes was informed by extensive medical literature linking them to adverse effects in the elderly, particularly those with compromised cognitive abilities.
The study’s findings unequivocally demonstrated a significant disparity in the prescription rates of these CNS-active medications across the different cognitive health groups. While 17% of older adults with normal cognition received such prescriptions, the rate escalated to nearly 22% among individuals classified as having cognitive impairment but no dementia. The highest prevalence was observed within the group of individuals diagnosed with dementia, where approximately 25% were prescribed these potentially problematic medications. This gradient of prescribing, with rates increasing alongside the severity of cognitive decline, highlights a critical area of concern for healthcare providers and policymakers alike.
Furthermore, the analysis delved into prescription trends categorized by specific medication types across all Medicare fee-for-service beneficiaries, revealing a complex landscape of drug utilization. While specific details of these breakdowns are not elaborated upon in the provided summary, this level of detail would typically involve examining the proportional use of each of the five drug categories within the overall prescribing landscape. For instance, it might reveal whether benzodiazepines or antipsychotics, for example, were the most frequently prescribed within the broader category of CNS-active drugs among dementia patients.
Despite the concerning findings regarding prescribing rates in vulnerable populations, the research also identified glimmers of progress and noted ongoing safety concerns. Prescriptions that were deemed clinically justified, meaning they had a clear and documented medical rationale, experienced a modest decline over the study period, decreasing from 6% in 2013 to 5.5% in 2021. Concurrently, prescriptions identified as likely inappropriate witnessed a more substantial reduction, falling from 15.7% to 11.4%. A significant portion of this improvement was attributed to a notable decrease in the utilization of benzodiazepines and sleep medications, alongside an overall reduction in prescriptions deemed inappropriate. This suggests that targeted interventions and awareness campaigns may be contributing to a more judicious use of certain drug classes.
However, the researchers were careful to acknowledge several limitations inherent in their study. Crucially, the analysis did not encompass data from Medicare Advantage plans, which represent a significant portion of Medicare beneficiaries. This exclusion means that the findings may not fully represent the prescribing practices across the entire Medicare population. Additionally, the study’s methodology might have overlooked certain nuanced clinical details, such as the specific presence or severity of agitation, which could influence prescribing decisions. The research also focused on the prevalence of prescriptions rather than quantifying the total cumulative exposure to these drugs over time, a factor that can significantly impact the manifestation of adverse effects.
Dr. Annie Yang, a scholar in the National Clinician Scholars Program at Yale University who spearheaded this study during her tenure as a UCLA internal medicine resident, emphasized the importance of a collaborative approach to medication management for older adults. She stated that while CNS-active prescriptions can be appropriate in certain clinical scenarios, it is imperative for older patients, or their designated caregivers, to engage in close and open communication with their physicians. This dialogue is essential to ensure that prescribed medications align with individual patient needs and circumstances. Dr. Yang further advised that when medications are deemed inappropriate, patients and their care teams should proactively explore alternative treatment strategies and carefully consider the feasibility and safety of gradually reducing or discontinuing the medication altogether. This recommendation underscores a patient-centered approach that prioritizes safety and well-being.
The groundbreaking research was the product of a collaborative effort involving several distinguished academics and institutions. Co-authors on the study included Mei Leng, Dr. Dan Ly, Chi-Hong Tseng, Dr. Catherine Sarkisian, and Nina Harawa, all affiliated with UCLA. Additionally, Cheryl Damberg from the RAND Corporation and Dr. A. Mark Fendrick from the University of Michigan contributed significantly to the study. Dr. Ly and Dr. Sarkisian also hold affiliations with the VA Greater Los Angeles Healthcare System, underscoring the interdisciplinary nature of the research. The funding for this critical investigation was generously provided by the National Institutes of Health and the National Institute on Aging, specifically through grant R01AG070017-01, a testament to the national importance placed on understanding and improving geriatric care.
About the Author
